BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, Futatsubashi M, Nakamura S. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39:961-8. [PMID: 15549449 DOI: 10.1007/s00535-004-1427-5] [Cited by in Crossref: 110] [Cited by in F6Publishing: 91] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Ansari D, Keussen I, Andersson R. Positron emission tomography in malignancies of the liver, pancreas and biliary tract – indications and potential pitfalls. Scandinavian Journal of Gastroenterology 2012;48:259-65. [DOI: 10.3109/00365521.2012.704936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016; 22(1): 232-252 [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
3 Yang SH, Suh K, Lee HW, Cho E, Cho JY, Cho YB, Yi N, Lee KU. The role of18F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-60. [DOI: 10.1002/lt.20861] [Cited by in Crossref: 112] [Cited by in F6Publishing: 102] [Article Influence: 7.0] [Reference Citation Analysis]
4 Ueda J, Yoshida H, Mamada Y, Taniai N, Mineta S, Yoshioka M, Kawano Y, Shimizu T, Hara E, Kawamoto C, Kaneko K, Uchida E. Surgical resection of a solitary para-aortic lymph node metastasis from hepatocellular carcinoma. World J Gastroenterol 2012; 18(23): 3027-3031 [PMID: 22736929 DOI: 10.3748/wjg.v18.i23.3027] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
5 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
6 Chin BB, Chang PP. Gastrointestinal malignancies evaluated with 18F-fluoro-2-deoxyglucose positron emission tomography. Best Practice & Research Clinical Gastroenterology 2006;20:3-21. [DOI: 10.1016/j.bpg.2005.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Hayashi H, Shimizu A, Motoyama H, Kubota K, Notake T, Sugenoya S, Hosoda K, Yasukawa K, Kobayashi R, Soejima Y. Usefulness and limitation of indocyanine green fluorescence for detection of peritoneal recurrence after hepatectomy for hepatocellular carcinoma: a case report. BMC Surg 2021;21:107. [PMID: 33653302 DOI: 10.1186/s12893-021-01111-8] [Reference Citation Analysis]
8 Agrawal A, Rangarajan V. Appropriateness criteria of FDG PET/CT in oncology. Indian J Radiol Imaging 2015;25:88-101. [PMID: 25969632 DOI: 10.4103/0971-3026.155823] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
9 Nagaoka S, Itano S, Ishibashi M, Torimura T, Baba K, Akiyoshi J, Kurogi J, Matsugaki S, Inoue K, Tajiri N, Takada A, Ando E, Kuromatsu R, Kaida H, Kurogi M, Koga H, Kumashiro R, Hayabuchi N, Kojiro M, Sata M. Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int 2006;26:781-8. [DOI: 10.1111/j.1478-3231.2006.01296.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
10 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Lee JE, Jang JY, Jeong SW, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Jin SY, Choi DL. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. World J Gastroenterol 2012; 18(23): 2979-2987 [PMID: 22736922 DOI: 10.3748/wjg.v18.i23.2979] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
12 Jin Y, Lee HC, Lee D, Shim JH, Kim KM, Lim Y, Do K, Ryu JS. Role of the routine use of chest computed tomography and bone scan in staging workup of hepatocellular carcinoma. Journal of Hepatology 2012;56:1324-9. [DOI: 10.1016/j.jhep.2011.12.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
13 Longo V, Brunetti O, D’oronzo S, Ostuni C, Gatti P, Silvestris F. Bone metastases in hepatocellular carcinoma: an emerging issue. Cancer Metastasis Rev 2014;33:333-42. [DOI: 10.1007/s10555-013-9454-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
14 Iwaki K, Ohta M, Ishio T, Kai S, Iwashita Y, Shibata K, Himeno K, Seike M, Fujioka T, Kitano S. Metastasis of hepatocellular carcinoma to spleen and small intestine. J Hepatobiliary Pancreat Surg 2008;15:213-9. [PMID: 18392718 DOI: 10.1007/s00534-007-1230-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
15 Tsurusaki M, Okada M, Kuroda H, Matsuki M, Ishii K, Murakami T. Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor. J Gastroenterol 2014;49:46-56. [PMID: 23525980 DOI: 10.1007/s00535-013-0790-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 2012;81:2417-22. [PMID: 21899970 DOI: 10.1016/j.ejrad.2011.08.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
17 Cheung TT, Chan SC, Ho CL, Chok KS, Chan AC, Sharr WW, Ng KK, Poon RT, Lo CM, Fan ST. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? Liver Transpl. 2011;17:1218-1225. [PMID: 21688383 DOI: 10.1002/lt.22362] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
18 Shimoda M, Iso Y, Tomita S, Fujimori T, Murakami K, Sawada T, Kubota K. Middle bile duct cancer with portal vein tumor thrombus. World J Surg Oncol 2008;6:48. [PMID: 18471304 DOI: 10.1186/1477-7819-6-48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Paspulati RM, Gupta A. PET/MR Imaging in Cancers of the Gastrointestinal Tract. PET Clin 2016;11:403-23. [PMID: 27593246 DOI: 10.1016/j.cpet.2016.05.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
20 Miller G, Schwartz LH, D'Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am. 2007;16:343-368. [PMID: 17560517 DOI: 10.1016/j.soc.2007.04.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
21 Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912-1921. [PMID: 18997056 DOI: 10.2967/jnumed.108.055087] [Cited by in Crossref: 169] [Cited by in F6Publishing: 139] [Article Influence: 12.1] [Reference Citation Analysis]
22 Kuehl H, Rosenbaum-Krumme S, Veit-Haibach P, Stergar H, Forsting M, Bockisch A, Antoch G. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography. Nucl Med Commun 2008;29:599-606. [PMID: 18528181 DOI: 10.1097/MNM.0b013e3282f8144d] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
24 Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019; 25(11): 1289-1306 [PMID: 30918424 DOI: 10.3748/wjg.v25.i11.1289] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
25 Buck AK, Herrmann K, Eckel F, Beer AJ. Pancreatic and hepatobiliary cancers. Methods Mol Biol 2011;727:243-64. [PMID: 21331938 DOI: 10.1007/978-1-61779-062-1_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Yang L, Marx H, Yen Y. Early finding of chest wall metastasis of hepatocellular carcinoma in a woman by fluorodeoxyglucose-positron emission tomography scan: a case report. J Med Case Rep 2011;5:147. [PMID: 21489297 DOI: 10.1186/1752-1947-5-147] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Liao X, Wei J, Li Y, Zhong J, Liu Z, Liao S, Li Q, Wei C. 18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual/recurrent hepatocellular carcinoma. Medicine (Baltimore). 2018;97:e11970. [PMID: 30142825 DOI: 10.1097/md.0000000000011970] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Kanazawa M, Sugaya T, Tominaga K, Takahashi F, Takenaka K, Nakano M, Hiraishi H. Jejunal Metastasis from Hepatocellular Carcinoma. Intern Med 2018;57:947-50. [PMID: 29269667 DOI: 10.2169/internalmedicine.9625-17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Buck AK, Stollfuss JC, Stahl A, Beer AJ, Meisetschläger G, Schwaiger M. Nuklearmedizinische Diagnostik von Lebertumoren. Internist 2007;48:21-9. [DOI: 10.1007/s00108-006-1769-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
30 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
31 Kamaleshwaran KK, Kashyap R, Bhattacharya A, Mittal BR. Solitary sternal metastasis from hepatocellular carcinoma detected by F-18 FDG PET/CT. Indian J Nucl Med. 2013;28:28-29. [PMID: 24019672 DOI: 10.4103/0972-3919.116810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
32 Lee JD, Kang WJ, Yun M. Primary Cancer of the Liver and Biliary Duct. PET Clin 2008;3:169-86. [PMID: 27156461 DOI: 10.1016/j.cpet.2008.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
33 Gauthé M, Richard-Molard M, Cacheux W, Michel P, Jouve JL, Mitry E, Alberini JL, Lièvre A; Fédération Francophone de Cancérologie Digestive (FFCD). Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis 2015;47:443-54. [PMID: 25766918 DOI: 10.1016/j.dld.2015.02.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
34 Refaat R, Basha MAA, Hassan MS, Hussein RS, El Sammak AA, El Sammak DAEA, Radwan MHS, Awad NM, Saad El-Din SA, Elkholy E, Ibrahim DRD, Saleh SA, Montasser IF, Said H. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma. Eur Radiol. 2018;28:5356-5367. [PMID: 29948070 DOI: 10.1007/s00330-018-5425-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
35 Talbot J, Michaud L, Grange J, Rosmorduc O, Balogova S. Use of choline PET for studying hepatocellular carcinoma. Clin Transl Imaging 2014;2:103-13. [DOI: 10.1007/s40336-014-0055-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
36 Lee M, Jeon JY, Neugent ML, Kim JW, Yun M. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. Clin Exp Metastasis. 2017;34:251-260. [PMID: 28429188 DOI: 10.1007/s10585-017-9847-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
37 Koch W, Tatsch K. Nuclear Medicine Procedures for Treatment Evaluation. In: Bilbao JI, Reiser MF, editors. Liver Radioembolization with 90Y Microspheres. Berlin: Springer Berlin Heidelberg; 2008. pp. 75-91. [DOI: 10.1007/978-3-540-35423-9_8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
38 Kawaoka T, Aikata H, Takaki S, Uka K, Azakami T, Saneto H, Jeong SC, Kawakami Y, Takahashi S, Toyota N. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res. 2009;39:134-142. [PMID: 19208034 DOI: 10.1111/j.1872-034x.2008.00416.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 10] [Article Influence: 3.9] [Reference Citation Analysis]
39 Yoo SW, Kim DY, Pyo A, Jeon S, Kim J, Kang SR, Cho SG, Lee C, Kim GJ, Song HC, Bom HS, Min JJ, Kwon SY. Differences in diagnostic impact of dual-tracer PET/computed tomography according to the extrahepatic metastatic site in patients with hepatocellular carcinoma.Nucl Med Commun. 2021;42:685-693. [PMID: 33625183 DOI: 10.1097/MNM.0000000000001382] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Sasaki A, Ishikawa K, Haraguchi N, Inoue H, Ishio T, Shibata K, Ohta M, Kitano S, Mori M. Receptor Activator of Nuclear Factor-κB Ligand (RANKL) Expression in Hepatocellular Carcinoma With Bone Metastasis. Ann Surg Oncol 2007;14:1191-9. [DOI: 10.1245/s10434-006-9277-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
41 Seo HJ, Kim GM, Kim JH, Kang WJ, Choi HJ. 18F-FDG PET/CT in hepatocellular carcinoma: detection of bone metastasis and prediction of prognosis. Nucl Med Commun. 2015;36:226-233. [PMID: 25460306 DOI: 10.1097/mnm.0000000000000246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
42 Kim YK, Lee KW, Cho SY, Han SS, Kim SH, Kim SK, Park SJ. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl. 2010;16:767-772. [PMID: 20517911 DOI: 10.1002/lt.22069] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
43 Kumar R, Chauhan A. Positron emission tomography: clinical applications in oncology. Part 2. Expert Rev Anticancer Ther 2006;6:625-40. [PMID: 16613549 DOI: 10.1586/14737140.6.4.625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
44 Wang T, Lei Y, Fu Y, Curran WJ, Liu T, Nye JA, Yang X. Machine learning in quantitative PET: A review of attenuation correction and low-count image reconstruction methods. Phys Med 2020;76:294-306. [PMID: 32738777 DOI: 10.1016/j.ejmp.2020.07.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
45 Fraum TJ, Ludwig DR, Hope TA, Fowler KJ. PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects. Gastroenterol Clin North Am 2018;47:691-714. [PMID: 30115444 DOI: 10.1016/j.gtc.2018.04.011] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
46 Lee JW, Paeng JC, Kang KW, Kwon HW, Suh K, Chung J, Lee MC, Lee DS. Prediction of Tumor Recurrence by 18 F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma. J Nucl Med 2009;50:682-7. [DOI: 10.2967/jnumed.108.060574] [Cited by in Crossref: 118] [Cited by in F6Publishing: 108] [Article Influence: 9.1] [Reference Citation Analysis]
47 Bates MJ, Farkas E, Taylor D, McFadden PM. Pulmonary resection of metastatic hepatocellular carcinoma after liver transplantation. Ann Thorac Surg. 2008;85:412-415. [PMID: 18222234 DOI: 10.1016/j.athoracsur.2007.10.065] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
48 Grassi I, Morigi JJ, Nanni C, Fanti S. FDG and other radiopharmaceuticals in the evaluation of liver lesions. Clin Transl Imaging 2014;2:115-27. [DOI: 10.1007/s40336-014-0059-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Dubash SR, Idowu OA, Sharma R. The emerging role of positron emission tomography in hepatocellular carcinoma. Hepat Oncol. 2015;2:191-200. [PMID: 30190998 DOI: 10.2217/hep.15.6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
50 Jadvar H. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: Potential role of other positron emission tomography radiotracers. Semin Nucl Med. 2012;42:247-254. [PMID: 22681673 DOI: 10.1053/j.semnuclmed.2012.02.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
51 De Gaetano AM, Rufini V, Castaldi P, Gatto AM, Filograna L, Giordano A, Bonomo L. Clinical applications of 18F-FDG PET in the management of hepatobiliary and pancreatic tumors. Abdom Imaging 2012;37:983-1003. [DOI: 10.1007/s00261-012-9845-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
52 Simoneau E, Hassanain M, Madkhali A, Salman A, Nudo CG, Chaudhury P, Metrakos P. (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. Curr Oncol. 2014;21:e551-e556. [PMID: 25089106 DOI: 10.3747/co.21.1959] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
53 Teixera SR, Kohan AA, Paspulati RM, Rong R, Herrmann KA. Potential Role of Positron Emission Tomography/Magnetic Resonance Imaging in Gastrointestinal and Abdominal Malignancies: Preliminary Experience. Seminars in Roentgenology 2014;49:321-33. [DOI: 10.1053/j.ro.2014.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
54 Shiomi S, Kawabe J. Clinical applications of positron emission tomography in hepatic tumors. Hepatol Res. 2011;41:611-617. [PMID: 21711419 DOI: 10.1111/j.1872-034x.2011.00819.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
55 Talbot J, Montravers F, Gutman F, Kerrou K, Huchet V, Grahek D, Andre T, Houry S, Touboul E, Rosmorduc O, Poupon R, Ruszniewski P, Rougier P, Grange J. Tomographie par émission de positons et cancers digestifs. La Presse Médicale 2008;37:e1-e24. [DOI: 10.1016/j.lpm.2007.03.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
56 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 685] [Article Influence: 57.0] [Reference Citation Analysis]
57 Hanajiri K, Mitsui H, Maruyama T, Kondo Y, Shiina S, Omata M, Nakagawa K. 18F-FDG PET for hepatocellular carcinoma presenting with portal vein tumor thrombus. J Gastroenterol. 2005;40:1005-1006. [PMID: 16261443 DOI: 10.1007/s00535-005-1667-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
58 Lee SD, Kim SH, Kim YK, Kim C, Kim SK, Han SS, Park SJ. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2013;26:50-60. [PMID: 23106431 DOI: 10.1111/j.1432-2277.2012.01572.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
59 Seo HJ, Choi YJ, Kim HJ, Jeong YH, Cho A, Lee JH, Yun M, Choi HJ, Lee JD, Kang WJ. Evaluation of Bone Metastasis from Hepatocellular Carcinoma Using (18)F-FDG PET/CT and (99m)Tc-HDP Bone Scintigraphy: Characteristics of Soft Tissue Formation. Nucl Med Mol Imaging 2011;45:203-11. [PMID: 24900005 DOI: 10.1007/s13139-011-0099-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Hatano E, Ikai I, Higashi T, Teramukai S, Torizuka T, Saga T, Fujii H, Shimahara Y. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006;30:1736-1741. [PMID: 16850145 DOI: 10.1007/s00268-005-0791-5] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 4.7] [Reference Citation Analysis]
61 Kornberg A, Friess H. 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches. Therap Adv Gastroenterol 2019;12:1756284819836205. [PMID: 30915167 DOI: 10.1177/1756284819836205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Yoon KT, Kim JK, Kim DY, Ahn SH, Lee JD, Yun M, Rha SY, Chon CY, Han KH. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology. 2007;72 Suppl 1:104-110. [PMID: 18087190 DOI: 10.1159/000111715] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 5.2] [Reference Citation Analysis]
63 Hsu CC, Chen CL, Wang CC, Lin CC, Yong CC, Wang SH, Liu YW, Lin TL, Lee WF, Lin YH, Chan YC, Wu YJ, Eng HL, Cheng YF. Combination of FDG-PET and UCSF Criteria for Predicting HCC Recurrence After Living Donor Liver Transplantation. Transplantation. 2016;100:1925-1932. [PMID: 27306534 DOI: 10.1097/tp.0000000000001297] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
64 Sung PS, Park HL, Yang K, Hwang S, Song MJ, Jang JW, Choi JY, Yoon SK, Yoo IR, Bae SH. 18F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. Eur J Nucl Med Mol Imaging. 2018;45:384-391. [PMID: 29124280 DOI: 10.1007/s00259-017-3871-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
65 Levy CS, Costa FGB, Faria DP, Stefano JT, Cogliati B, Oliveira CP. 18F-FDG PET/CT as an assessment tool of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease development in experimental model.Arq Gastroenterol. 2019;56:45-50. [PMID: 31141073 DOI: 10.1590/S0004-2803.201900000-02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, Guan Y, Jia H, Chen J, Lu L, Xie F, Qin L. 68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. Front Oncol 2021;11:693640. [PMID: 34249748 DOI: 10.3389/fonc.2021.693640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
67 Sørensen M, Frisch K, Bender D, Keiding S. The potential use of 2-[18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2011;38:1723-1731. [PMID: 21553087 DOI: 10.1007/s00259-011-1831-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
68 Bak-Fredslund KP, Munk OL, Keiding S, Sørensen M. 2-[(18)F]fluoro-2-deoxy-D-galactose PET/CT of hepatocellular carcinoma is not improved by co-administration of galactose. Nucl Med Biol 2016;43:577-80. [PMID: 27434609 DOI: 10.1016/j.nucmedbio.2016.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
69 Murakami K. FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations. World J Clin Oncol 2011; 2(5): 229-236 [PMID: 21611100 DOI: 10.5306/wjco.v2.i5.229] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
70 Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? PLoS One 2014;9:e105679. [PMID: 25153834 DOI: 10.1371/journal.pone.0105679] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
71 Mocherla B, Kim J, Roayaie S, Kim S, Machac J, Kostakoglu L. FDG PET/CT imaging to rule out extrahepatic metastases before liver transplantation. Clin Nucl Med. 2007;32:947-948. [PMID: 18030049 DOI: 10.1097/rlu.0b013e3181598cef] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
72 Huo L, Wu Z, Zhuang H, Fu Z, Dang Y. Dual time point C-11 acetate PET imaging can potentially distinguish focal nodular hyperplasia from primary hepatocellular carcinoma. Clin Nucl Med. 2009;34:874-877. [PMID: 20139820 DOI: 10.1097/rlu.0b013e3181bed06e] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
73 Sharma B, Martin A, Zerizer I. Positron Emission Tomography-Computed Tomography in Liver Imaging. Seminars in Ultrasound, CT and MRI 2013;34:66-80. [DOI: 10.1053/j.sult.2012.11.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
74 Kawamura E, Shiomi S, Kotani K, Kawabe J, Hagihara A, Fujii H, Uchida-Kobayashi S, Iwai S, Morikawa H, Enomoto M, Murakami Y, Tamori A, Kawada N. Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:1722-7. [PMID: 24730671 DOI: 10.1111/jgh.12611] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
75 Esteves FP, Schuster DM, Halkar RK. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med. 2006;36:169-181. [PMID: 16517238 DOI: 10.1053/j.semnuclmed.2005.12.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
76 Sun L, Wu H, Guan YS. Positron emission tomography/computer tomography: Challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol 2007; 13(20): 2775-2783 [PMID: 17569111 DOI: 10.3748/wjg.v13.i20.2775] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
77 Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, Schuster T, Langer R, Wester HJ, Schmid RM. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med. 2009;50:1441-1447. [PMID: 19690030 DOI: 10.2967/jnumed.109.065896] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
78 Sotiropoulos GC, Kuehl H, Sgourakis G, Molmenti EP, Beckebaum S, Cicinnati VR, Baba HA, Schmitz KJ, Broelsch CE, Lang H. Pulmonary nodules at risk in patients undergoing liver transplantation for hepatocellular carcinoma. Transplant International 2008;21:850-6. [DOI: 10.1111/j.1432-2277.2008.00688.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
79 Hellman RS, Krasnow AZ, Sudakoff GS. Positron Emission Tomography for Staging and Assessment of Tumor Response of Hepatic Malignancies. Seminars Intervent Radiol. 2006;23:21-32. [PMID: 21326717 DOI: 10.1055/s-2006-939838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
80 Hwang S, Lee S, Joh J, Suh K, Kim D. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: Comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005;11:1265-72. [DOI: 10.1002/lt.20549] [Cited by in Crossref: 162] [Cited by in F6Publishing: 150] [Article Influence: 9.5] [Reference Citation Analysis]
81 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
82 Ronot M, Clift AK, Vilgrain V, Frilling A. Functional imaging in liver tumours. J Hepatol 2016;65:1017-30. [PMID: 27395013 DOI: 10.1016/j.jhep.2016.06.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
83 Na SJ, Oh JK, Hyun SH, Lee JW, Hong IK, Song BI, Kim TS, Eo JS, Lee SW, Yoo IR, Chung YA, Yun M. 18F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma Patients: A Multicenter Retrospective Cohort Study. J Nucl Med. 2017;58:730-736. [PMID: 27789714 DOI: 10.2967/jnumed.116.182022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
84 Blechacz B, Gores GJ. Positron emission tomography scan for a hepatic mass. Hepatology. 2010;52:2186-2191. [PMID: 20967825 DOI: 10.1002/hep.24002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
85 Xia F, Wu L, Lau WY, Li G, Huan H, Qian C, Ma K, Bie P. Positive lymph node metastasis has a marked impact on the long-term survival of patients with hepatocellular carcinoma with extrahepatic metastasis. PLoS One. 2014;9:e95889. [PMID: 24760012 DOI: 10.1371/journal.pone.0095889] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
86 Jo H, Lee J, Jeon J, Kim SY, Chung JI, Ko HY, Lee M, Yun M. The critical role of glucose deprivation in epithelial-mesenchymal transition in hepatocellular carcinoma under hypoxia. Sci Rep 2020;10:1538. [PMID: 32001727 DOI: 10.1038/s41598-020-58124-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
87 Tan CH, Low SC, Thng CH. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol. 2011;2011:519783. [PMID: 22007313 DOI: 10.4061/2011/519783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
88 Howard BA, Wong TZ. 18F-FDG-PET/CT Imaging for Gastrointestinal Malignancies. Radiol Clin North Am 2021;59:737-53. [PMID: 34392916 DOI: 10.1016/j.rcl.2021.06.001] [Reference Citation Analysis]
89 Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018; 10(10): 336-343 [PMID: 30364796 DOI: 10.4251/wjgo.v10.i10.336] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
90 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
91 Maniaci V, Davidson BR, Rolles K, Dhillon AP, Hackshaw A, Begent RH, Meyer T. Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. Eur J Surg Oncol 2009;35:617-21. [PMID: 19144491 DOI: 10.1016/j.ejso.2008.12.009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
92 Yoo SW, Kim DY, Lee C, Min JJ, Kwon SY. Small Bowel Metastasis From Hepatocellular Carcinoma Detected by 18F-FDG PET/CT But Not by 11C-Acetate PET/CT. Clin Nucl Med 2017;42:966-7. [PMID: 29076914 DOI: 10.1097/RLU.0000000000001882] [Reference Citation Analysis]
93 Hayakawa N, Nakamoto Y, Nakatani K, Hatano E, Seo S, Higashi T, Saga T, Uemoto S, Togashi K. Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients. Int J Clin Oncol. 2014;19:1020-1028. [PMID: 24366329 DOI: 10.1007/s10147-013-0653-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
94 Kato H, Fukuchi M, Miyazaki T, Nakajima M, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Manda R, Ojima H, Tsukada K, Oriuchi N, Endo K, Kuwano H. Positron emission tomography in esophageal cancer. Esophagus 2005;2:111-21. [DOI: 10.1007/s10388-005-0053-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]